Cluster of hemolytic-uremic syndrome caused by Shiga toxin-producing Escherichia coli O26:H11
暂无分享,去创建一个
H. Karch | U. John | J. Misselwitz | L. Patzer | G. Rönnefarth | F. Ringelmann | Martina Bielazewska
[1] J. Janda,et al. Vero cytotoxin-producing strains of Escherichia coli in children with haemolytic uraemic syndrome and diarrhoea in Czechoslovakia , 1990, Infection.
[2] C. Bréchot,et al. Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection. , 2003, Journal of hepatology.
[3] B. Dikici,et al. Combination therapy for children with chronic hepatitis B virus infection , 2002, Journal of gastroenterology and hepatology.
[4] J. Bockemühl,et al. Infektionen des Menschen durch enterohämorrhagische Escherichia coli (EHEC) in der Bundesrepublik Deutschland von 1998 bis 2001 Prävalenz und Typenspektrum , 2002, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.
[5] N. Okamura,et al. Epidemiol. Infect. 127 (2001), 221–7 An outbreak of diarrhoea due to multiple antimicrobial-resistant Shiga toxin-producing Escherichia coli O26: H11 in a nursery , 2002, Epidemiology and Infection.
[6] N. Okamura,et al. An outbreak of diarrhoea due to multiple antimicrobial-resistant Shiga toxin-producing Escherichia coli O26[ratio ]H11 in a nursery , 2001, Epidemiology and Infection.
[7] B. Dikici,et al. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. , 2001, The Pediatric infectious disease journal.
[8] D. V. van Thiel,et al. Increased effective immunogenicity to high‐dose and short‐interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis , 2001, Journal of viral hepatitis.
[9] A. Siitonen,et al. Clinical Isolates of Non-O157 Shiga Toxin-ProducingEscherichia coli: Serotypes, Virulence Characteristics, and Molecular Profiles of Strains of the Same Serotype , 2001, Journal of Clinical Microbiology.
[10] C. Bréchot,et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. , 2001, Journal of hepatology.
[11] T. Cheasty,et al. Verocytotoxin-Producing Escherichia coli Serotype O26 : H11 Outbreak in an Irish Crèche , 2001, European Journal of Clinical Microbiology and Infectious Diseases.
[12] G. Ogg,et al. Lamivudine treatment can overcome cytotoxic T‐cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy , 2001, Hepatology.
[13] J. H. Green,et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. , 2001, The Journal of infectious diseases.
[14] C. Bréchot,et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. , 2001, Vaccine.
[15] H. Karch,et al. Non-O157:H7 Shiga toxin (verocytotoxin)-producing Escherichia coli strains: epidemiological significance and microbiological diagnosis , 2000 .
[16] A. Caprioli,et al. Typing of Intimin Genes in Human and Animal Enterohemorrhagic and Enteropathogenic Escherichia coli: Characterization of a New Intimin Variant , 2000, Infection and Immunity.
[17] H. Karch,et al. Molecular characteristics and epidemiological significance of Shiga toxin-producing Escherichia coli O26 strains. , 2000, Journal of clinical microbiology.
[18] H. Karch,et al. Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections. , 1999, Diagnostic microbiology and infectious disease.
[19] C. Bréchot,et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. , 1999, The Journal of infectious diseases.
[20] F. Mahoney,et al. Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection , 1999, Clinical Microbiology Reviews.
[21] T. Kawakita,et al. Epidemic of Gastrointestinal Tract Infection Including Hemorrhagic Colitis Attributable to Shiga Toxin 1-producingEscherichia coli O118:H2 at a Junior High School in Japan , 1999, Pediatrics.
[22] A. Bertoletti,et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. , 1998, The Journal of clinical investigation.
[23] E. Avner,et al. Cholelithiasis following Escherichia coli O157 : H7-associated hemolytic uremic syndrome , 1998, Pediatric Nephrology.
[24] H. Karch,et al. Shiga Toxin-Producing Escherichia coli Infections in Germany †. , 1997, Journal of food protection.
[25] H. Karch,et al. EspP, a novel extracellular serine protease of enterohaemorrhagic Escherichia coli O157:H7 cleaves human coagulation factor V , 1997, Molecular microbiology.
[26] H. Karch,et al. A gene cluster closely related to type II secretion pathway operons of gram-negative bacteria is located on the large plasmid of enterohemorrhagic Escherichia coli O157 strains. , 1997, FEMS microbiology letters.
[27] I. Capek,et al. Possible person-to-person transmission of Escherichia coli O111 – associated hemolytic uremic syndrome , 1997, Pediatric Nephrology.
[28] J. H. Green,et al. Shiga-like toxin-producing Escherichia coli O111 and associated hemolytic-uremic syndrome: a family outbreak. , 1996, The Pediatric infectious disease journal.
[29] H. Karch,et al. KatP, a novel catalase-peroxidase encoded by the large plasmid of enterohaemorrhagic Escherichia coli O157:H7. , 1996, Microbiology.
[30] J. Lanser,et al. Molecular microbiological investigation of an outbreak of hemolytic-uremic syndrome caused by dry fermented sausage contaminated with Shiga-like toxin-producing Escherichia coli , 1996, Journal of clinical microbiology.
[31] J. Janda,et al. Verocytotoxin-producing Escherichia coli in children with hemolytic uremic syndrome in the Czech Republic. , 1996, Clinical nephrology.
[32] J. Blanco,et al. Brote de gastroenteritis asociado con un Escherichia coli verotoxigénico (ECVT) O111:H-VT1+ eae+ , 1996 .
[33] L. Beutin,et al. Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933 , 1995, Infection and immunity.
[34] W. L. Payne,et al. Simultaneous identification of strains of Escherichia coli serotype O157:H7 and their Shiga-like toxin type by mismatch amplification mutation assay-multiplex PCR , 1995, Journal of clinical microbiology.
[35] F. Chisari,et al. Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.
[36] R. L. Guerrant,et al. Escherichia coli O157:H7. , 1995, The New England journal of medicine.
[37] A. Vitiello,et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. , 1995, The Journal of clinical investigation.
[38] Serotype O104H. Outbreak of acute gastroenteritis attributable to Escherichia coli serotype O104:H21--Helena, Montana, 1994. , 1995, MMWR. Morbidity and mortality weekly report.
[39] H. Karch,et al. Prevalence of attaching and effacing Escherichia coli in stool samples from patients and controls. , 1994, Zentralblatt fur Bakteriologie : international journal of medical microbiology.
[40] A. Edefonti,et al. Communitywide Outbreak of Hemolytic-Uremic Syndrome Associated with Non-O157 Verocytotoxin-Producing Escherichia coli , 1994 .
[41] A. Edefonti,et al. Community-wide outbreak of hemolytic-uremic syndrome associated with non-O157 verocytotoxin-producing Escherichia coli. , 1994, The Journal of infectious diseases.
[42] A. Lok,et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. , 1993, Gastroenterology.
[43] I. Lauder,et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. , 1992, Gastroenterology.
[44] H. Karch,et al. Indirect hemagglutination assay for diagnosis of Escherichia coli O157 infection in patients with hemolytic-uremic syndrome , 1992, Journal of clinical microbiology.
[45] U. Spengler,et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. , 1991, Journal of hepatology.
[46] H. Suzuki. [Treatment of hepatitis B]. , 1990, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.
[47] A. Lok,et al. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. , 1987, Lancet.
[48] H. Lior,et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. , 1985, The Journal of infectious diseases.
[49] J. Wells,et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. , 1983, The New England journal of medicine.
[50] M. Petric,et al. SPORADIC CASES OF HAEMOLYTIC-URAEMIC SYNDROME ASSOCIATED WITH FAECAL CYTOTOXIN AND CYTOTOXIN-PRODUCING ESCHERICHIA COLI IN STOOLS , 1983, The Lancet.
[51] R. Fieve,et al. Letter: How blind is the double-blind?: an assessment in a lithium-prophylaxis study. , 1974, Lancet.
[52] S. Cutillo. [Hemolytic-uremic syndrome]. , 1973, La Pediatria.